

Coronavirus Disease 2019 (COVID-19) Situation Report



Weekly Report No. 264 - Saudi Arabia

11 - 17 November, 2021

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Current	254,256,432	5,112,461	16,606,067	306,272
Last Week	250,715,502	5,062,106	16,509,896	304,294

Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	549,339	538,412	8,820	2,107	47	30,964,745
in 7 days						
10/11/2021	43	51	2	2,194	46	42,741
11/11/2021	45	60	1	2,178	53	40,461
12/11/2021	44	41	1	2,180	51	27,402
13/11/2021	30	73	2	2,135	52	36,678
14/11/2021	38	55	3	2,115	49	35,022
15/11/2021	37	44	2	2,106	50	32,753
16/11/2021	42	39	2	2,107	47	33,208

Vaccination in KSA

Total Doses Administered	Total of 1 Dose	Total of 2 Doses	Total of 3 Doses
46.9 million	24.5 million	22.1 million	0.3 million

HIGHLIGHTS

- Regions with the highest new infections over the past 7 days: Riyadh followed by Makkah.
- Ministry of Health includes the Moderna vaccine along with Pfizer vaccine for booster doses.
- Ministry of Human Resources: Immunization rate in the public sector with 2 doses reached 95.5% and 92.5% in the private sector.
- MoH: 97% of people infected with Covid-19 during the past two months did not receive the vaccine, or only took one dose.
- Ministry of Education: Students of intermediate and secondary public schools will sit for their first in-person examination in 2 years.
- Overseas pilgrims can apply for Umrah, prayer, visit permits via Eatmarna and Tawakkalna apps. after registering on the "Quddum" platform.
- Transport Authority announces the use of the full seat capacity of buses inside cities.
- Ministry of Interior records 837 violations against precautionary measures nationally in 1 week. The highest number was recorded in the Makkah Region whereas the smallest number was in Najran and Northern Borders.
- WHO Publishes Injection safety in the context of coronavirus disease (COVID-19) vaccination.
- WHO launches Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19.
- WHO publishes WHO COVID-19 Excess Mortality Estimation Methodology, see link.
- WHO launches the Guidance on operational microplanning for COVID-19 vaccination, see link.
- WHO publishes recommendations on the Co-administration of seasonal inactivated influenza and COVID-19 vaccines, see link.
- WHO publishes technical specifications and implementation guidance for digital documentation of COVID-19 vaccination status, see link.
- WHO publishes holding gatherings during the COVID-19 pandemic: WHO policy brief, see link.
- WHO publishes An overview of infodemic management during COVID-19, January 2020–May 2021, see link.

IMPORTANT LINKS

- **MoH COVID-19 updates:** <https://twitter.com/saudimoh>
- **WHO's COVID-19 global situation reports:** <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- **WHO's COVID-19 dashboard:** <https://covid19.who.int/>
- **MoH COVID-19 dashboard:** <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- **Injection safety in the context of coronavirus disease (COVID-19) vaccination:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy-brief-Vaccination-Injection-safety>
- **Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin>
- **WHO COVID-19 Excess Mortality Estimation Methodology:** <https://www.who.int/publications/i/item/who-covid-19-excess-mortality-estimation-methodology>
- **Guidance on operational microplanning for COVID-19 vaccination:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-microplanning-2021.1>
- **WHO recommendations on the co-administration of COVID-19 and influenza vaccines:** [Coadministration of seasonal inactivated influenza and COVID-19 vaccines \(who.int\)](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin)
- **Digital Documentation of COVID-19 Certificates: Vaccination Status:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Digital_certificates-vaccination-technical_briefing-2021.1
- **Holding gatherings during the COVID-19 pandemic: WHO policy brief:** <https://www.who.int/publications/i/item/holding-gatherings-during-the-covid-19-pandemic-who-policy-brief-2-august-2021>
- **An overview of infodemic management during COVID-19, January 2020–May 2021:** <https://www.who.int/publications/i/item/9789240035966>

IMPORTANT DEVELOPMENTS

WHO issues emergency use listing for COVAXIN® COVID-19 vaccine





The World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN® (developed by Bharat Biotech - India), on 3 November 2021 for the prevention of COVID-19.

COVAXIN® was assessed under the WHO EUL procedure based on the review of data on quality, safety, efficacy, a risk management plan and programmatic suitability. The Technical Advisory Group (TAG), convened by WHO has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs risks and the vaccine can be used globally.

The vaccine is formulated from an inactivated SARS-CoV-2 antigen. WHO recommends the use of the vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above. COVAXIN® was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements. Available data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned.

As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.

Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products said “This emergency use listing expands the availability of vaccines, the most effective medical tool we have to end the pandemic,”



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa

